Telehealth GLP-1 Prescriptions Surge 340% as Regulatory Barriers Ease
GLP-1 Authority Editorial Team
Medical News Desk
Online prescribing platforms report record demand for GLP-1 consultations following DEA rule changes that permanently allow telehealth prescribing of non-controlled medications without prior in-person visits.
Key Points
- Telehealth GLP-1 prescriptions increased 340% year-over-year following DEA rule change
- Multiple major telehealth platforms now offer GLP-1 prescribing services
- Average time from consultation to first dose: 4 to 7 days via telehealth
- Telehealth platforms now account for an estimated 28% of all new GLP-1 prescriptions
- Concerns raised about adequacy of medical evaluation in some telehealth models
The Telehealth GLP-1 Boom
Telehealth platforms specializing in GLP-1 prescriptions have reported explosive growth following the DEA's 2023 rule permanently allowing telehealth prescribing of non-controlled medications without a prior in-person visit. Industry data shows a 340% year-over-year increase in telehealth GLP-1 consultations, with major platforms collectively serving an estimated 2.1 million active GLP-1 patients as of Q1 2026.
Major Telehealth Platforms
The telehealth GLP-1 market is dominated by several major platforms offering a range of services and pricing models. Some platforms offer GLP-1 medications starting at $199 per month, while others provide comprehensive obesity medicine programs that combine prescriptions with behavioral coaching. Each platform has different pricing, drug availability, and clinical protocols. Our Buying Guide provides a detailed comparison to help you make an informed decision.
Speed and Convenience
The primary appeal of telehealth GLP-1 prescribing is speed and convenience. Patients can complete an online intake form, have a video or asynchronous consultation with a licensed provider, and receive a prescription within 24 to 72 hours — compared to weeks or months for an in-person appointment with an endocrinologist or obesity medicine specialist. For patients in rural areas or those with limited access to specialists, telehealth may be the only practical option.
Quality and Safety Concerns
The rapid growth of telehealth GLP-1 prescribing has raised concerns among some medical organizations. The Obesity Medicine Association and the American Association of Clinical Endocrinology have published guidance emphasizing that appropriate GLP-1 prescribing requires a thorough medical evaluation, including review of contraindications, relevant medical history, and baseline laboratory tests. Some telehealth platforms have been criticized for inadequate evaluation processes, particularly for asynchronous (non-video) consultations.
Compounded GLP-1 and Telehealth
Many telehealth platforms, particularly those offering lower prices, have been prescribing compounded semaglutide from 503B outsourcing facilities. With the FDA removing semaglutide from the drug shortage list, compounding pharmacies are required to phase out compounded versions by mid-2026. This is expected to significantly impact the pricing and availability of lower-cost telehealth GLP-1 options. Patients currently on compounded semaglutide should discuss transition plans with their telehealth provider.
How to Choose a Telehealth Platform
When selecting a telehealth platform for GLP-1 prescribing, consider the following factors: (1) Does the platform offer the specific medication you need? (2) What is the total monthly cost, including the medication? (3) Does the platform accept your insurance? (4) What is the clinical evaluation process — is it a video visit or asynchronous? (5) What ongoing support is provided? Our Buying Guide provides a detailed comparison of the major platforms to help you make an informed decision.
Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication.